Impact of an Electronic Cigarette on Smoking Reduction and Cessation in Schizophrenic Smokers: A Prospective 12-Month Pilot Study

  title={Impact of an Electronic Cigarette on Smoking Reduction and Cessation in Schizophrenic Smokers: A Prospective 12-Month Pilot Study},
  author={Pasquale Caponnetto and Roberta Auditore and Cristina Russo and Giorgio Carlo Cappello and Riccardo Polosa},
  journal={International Journal of Environmental Research and Public Health},
  pages={446 - 461}
Background: Cigarette smoking is a tough addiction to break. This dependence is the most common dual diagnosis for individuals with schizophrenia. Currently three effective drugs are approved for smoking cessation: nicotine replacement therapy (NRT), varenicline and bupropion. However, some serious side effects of varenicline have been reported, including depression, suicidal thoughts, and suicide. The use of bupropion also has side effects. It should not be used by people who have epilepsy or… 

Figures and Tables from this paper

Smoking Cessation and Reduction in Schizophrenia (SCARIS) with e-cigarette: study protocol for a randomized control trial

The goal is to propose an effective intervention to reduce the risk of tobacco smoking, as a complementary tool to treat tobacco addiction in schizophrenia, in schizophrenic smokers not intending to quit.

Approved and emerging smoking cessation treatments for people with schizophrenia spectrum disorders: A narrative review

E-cigarettes could be considered as an applicable instrument for Tobacco Harm Reduction (THR) and smoking cessation and evidence suggests that they may effective as smoking cessation tool and may be less harmful alternatives to combustible cigarette smoking.

A pre-post pilot study of electronic cigarettes to reduce smoking in people with severe mental illness

The provision of e-cigarettes is a potentially useful harm reduction intervention in smokers with a psychotic disorder and is verified by significant carbon monoxide reductions between these time points.

Cigarette Smoking and Schizophrenia: Etiology, Clinical, Pharmacological, and Treatment Implications

Smokers with schizophrenia are more likely to have more intense positive symptoms and lower cognitive function, but diminished intensity of extrapyramidal side effects than nonsmoking patients with schizophrenia, which could suggest higher levels of baseline aggression.

E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial

For people with mental illness, e-cigarettes may be as effective and safe as patches, yet more acceptable, and associated with greater smoking reduction.

Impact of E-cigarettes on Smoking and Related Outcomes in Veteran Smokers With Psychiatric Comorbidity

E-cigarettes appear to be a viable harm reduction modality in smokers with psychiatric comorbidities, as indicated by sustained and frequent e-cigarette use by 90% of participants and may promote reduction and/or cessation of combustible cigarette use.

Treatment of Tobacco Use Disorders in Smokers with Serious Mental Illness: Toward Clinical Best Practices

Converging evidence indicates that a majority of smokers with serious mental illness want to quit smoking and that available pharmacotherapeutic cessation aids combined with behavioral support are both effective for, and well tolerated by, these smokers.

Existing and emerging smoking cessation options for people with schizophrenia spectrum disorders

The vulnerability of smokers with SSD is demonstrated and underscores the need for research in these areas with large enough sample sizes to detect treatment effects, as well as more research to develop the evidence-base for e-cigarettes intervention.



Smoking, quitting, and psychiatric disease: A review

Acute feasibility and safety of a smoking reduction strategy for smokers with schizophrenia.

  • G. DalackJ. Meador-Woodruff
  • Medicine, Psychology
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
  • 1999
Significant decreases in carbon monoxide smoking indices were seen for the heaviest smokers, suggesting further investigation of a smoking reduction intervention in this population of heavy smokers with schizophrenia.

Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia.

The results suggest that specialized group therapy for schizophrenic patients is not significantly different from American Lung Association group therapy in its effect on smoking cessation, and atypical agents may be superior to typical agents in combination with the nicotine transdermal patch for smoking cessation in schizophrenia.

Effect of a nicotine-free inhalator as part of a smoking-cessation programme

The results of the logistic model analysis indicate that a high GN-SBQ score is a strong independent predictor for successful quitting at 24 weeks in the PAIPO group, and nicotine-free inhalators may be beneficial when used in the context of smoking-cessation interventions.

A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia.

It is suggested that bupropion SR, 150 mg/day, combined with CBT, may facilitate smoking reduction in patients with schizophrenia while stabilizing psychiatric symptoms during a quit attempt.

Smoking and vulnerability for schizophrenia.

  • J. de Leon
  • Medicine, Psychology
    Schizophrenia bulletin
  • 1996
The increased early onset suggests that familial factors may increase the prevalence of smoking even among patients who have not yet shown psychotic symptoms, and it is hypothesized that smoking among family members in families with genetic loading for schizophrenia may be a marker for those at risk of developing schizophrenia.

Nicotine–Haloperidol Interactions and Cognitive Performance in Schizophrenics

Reduced-nicotine content cigarettes: Is there potential to aid smoking cessation?

  • N. WalkerC. BullenH. McRobbie
  • Medicine, Psychology
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
  • 2009
Three clinical trials that suggest that smokers can dissociate nicotine delivery from the act of smoking if they use reduced-nicotine content cigarettes in combination with nicotine replacement therapy are identified.

A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder.

Varenicline was well tolerated, with no evidence of exacerbation of symptoms, and was associated with significantly higher smoking cessation rates versus placebo at 12 weeks, suggesting varenic line is a suitable smoking cessation therapy for patients with schizophrenia or schizoaffective disorder.